Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MASTER-IgAN Real-World Study of Oral Methylprednisolone and Sequential Telitacicept in IgA Nephropathy
ChiCTR2600128575Phase 4Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of methylprednisolone and telitacicept in IgA nephropathy (IgAN) (3 arms), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoint: Change in 24-hour urinary protein from baseline at 36 weeks of follow-up. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
methylprednisolonetelitacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2600128575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128575.